Archive for the ‘Pharma and Medical Device’ Category

A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target

Posted by Michael A. S. Guth on March 30th, 2026

Forthcoming inย Drug Discovery Today: A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target I am pleased to announce that my article, “Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation,” has been accepted for publication inย Drug Discovery Today, a leading journal for pharmaceutical strategy and […]

Posted in Neuroplasticity, Pharma and Medical Device Comments Off on A New Blueprint for Turning an Orphan Brain Receptor into a Blockbuster Drug Target
Read More »

“Chemo Brain” and Diabetes Research

Posted by Michael A. S. Guth on February 10th, 2026

Is the Next Breakthrough in “Chemo Brain” Treatment Hiding in Diabetes Research? For cancer survivors, the battle often doesn’t end with remission. Chemotherapy-Induced Cognitive Impairment (CICI)โ€”widely known as “Chemo Brain”โ€”remains one of the most debilitating long-term side effects of treatment, affecting memory, executive function, and attention. While the clinical impact is well-documented, therapeutic options remain […]

Posted in Featured, Neuroplasticity, Pharma and Medical Device Comments Off on “Chemo Brain” and Diabetes Research
Read More »

๐–๐ก๐ฒ ๐ƒ๐๐€ ๐Ž๐ซ๐ข๐ ๐š๐ฆ๐ข ๐ข๐ฌ ๐ญ๐ก๐ž ๐’๐ž๐œ๐ซ๐ž๐ญ ๐ญ๐จ ๐š “๐’๐ข๐ฅ๐ž๐ง๐ญ” ๐•๐š๐œ๐œ๐ข๐ง๐ž ๐’๐œ๐š๐Ÿ๐Ÿ๐จ๐ฅ๐ ๐ˆ๐ง ๐ฏ๐š๐œ๐œ๐ข๐ง๐ž ๐๐ž๐ฌ๐ข๐ ๐ง,

Posted by Michael A. S. Guth on February 7th, 2026

๐–๐ก๐ฒ ๐ƒ๐๐€ ๐Ž๐ซ๐ข๐ ๐š๐ฆ๐ข ๐ข๐ฌ ๐ญ๐ก๐ž ๐’๐ž๐œ๐ซ๐ž๐ญ ๐ญ๐จ ๐š “๐’๐ข๐ฅ๐ž๐ง๐ญ” ๐•๐š๐œ๐œ๐ข๐ง๐ž ๐’๐œ๐š๐Ÿ๐Ÿ๐จ๐ฅ๐ ๐ˆ๐ง ๐ฏ๐š๐œ๐œ๐ข๐ง๐ž ๐๐ž๐ฌ๐ข๐ ๐ง, “๐จ๐Ÿ๐Ÿ-๐ญ๐š๐ซ๐ ๐ž๐ญ” ๐ซ๐ž๐ฌ๐ฉ๐จ๐ง๐ฌ๐ž๐ฌ ๐š๐ซ๐ž ๐š ๐ฉ๐ž๐ซ๐ฌ๐ข๐ฌ๐ญ๐ž๐ง๐ญ ๐ก๐ฎ๐ซ๐๐ฅ๐ž. ๐–๐ก๐ž๐ง ๐ฐ๐ž ๐ฎ๐ฌ๐ž ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง-๐›๐š๐ฌ๐ž๐ ๐ฉ๐š๐ซ๐ญ๐ข๐œ๐ฅ๐ž๐ฌ ๐ญ๐จ ๐๐ž๐ฅ๐ข๐ฏ๐ž๐ซ ๐š๐ง ๐š๐ง๐ญ๐ข๐ ๐ž๐ง, ๐ญ๐ก๐ž ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ ๐จ๐Ÿ๐ญ๐ž๐ง ๐ ๐ž๐ญ๐ฌ ๐๐ข๐ฌ๐ญ๐ซ๐š๐œ๐ญ๐ž๐ ๐š๐ง๐ ๐š๐ญ๐ญ๐š๐œ๐ค๐ฌ ๐ญ๐ก๐ž ๐๐ž๐ฅ๐ข๐ฏ๐ž๐ซ๐ฒ ๐ฏ๐ž๐ก๐ข๐œ๐ฅ๐ž ๐ข๐ญ๐ฌ๐ž๐ฅ๐Ÿ ๐ข๐ง๐ฌ๐ญ๐ž๐š๐ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ฏ๐ข๐ซ๐ฎ๐ฌ. ๐๐ž๐ฐ ๐ซ๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐Ÿ๐ซ๐จ๐ฆ ๐Œ๐ˆ๐“ ๐š๐ง๐ ๐’๐œ๐ซ๐ข๐ฉ๐ฉ๐ฌ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก, ๐ฉ๐ฎ๐›๐ฅ๐ข๐ฌ๐ก๐ž๐ ๐ข๐ง ๐’๐œ๐ข๐ž๐ง๐œ๐ž, […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐–๐ก๐ฒ ๐ƒ๐๐€ ๐Ž๐ซ๐ข๐ ๐š๐ฆ๐ข ๐ข๐ฌ ๐ญ๐ก๐ž ๐’๐ž๐œ๐ซ๐ž๐ญ ๐ญ๐จ ๐š “๐’๐ข๐ฅ๐ž๐ง๐ญ” ๐•๐š๐œ๐œ๐ข๐ง๐ž ๐’๐œ๐š๐Ÿ๐Ÿ๐จ๐ฅ๐ ๐ˆ๐ง ๐ฏ๐š๐œ๐œ๐ข๐ง๐ž ๐๐ž๐ฌ๐ข๐ ๐ง,
Read More »

๐—ก๐—œ๐—–๐—˜ ๐—ฅ๐—ฒ๐—ฐ๐—ผ๐—บ๐—บ๐—ฒ๐—ป๐—ฑ๐˜€ ๐——๐˜‚๐—ฝ๐—ถ๐—น๐˜‚๐—บ๐—ฎ๐—ฏ ๐—ณ๐—ผ๐—ฟ ๐—˜๐—ผ๐˜€๐—ถ๐—ป๐—ผ๐—ฝ๐—ต๐—ถ๐—น๐—ถ๐—ฐ ๐—–๐—ข๐—ฃ๐——: ๐—” ๐——๐—ฒ๐—ฒ๐—ฝ ๐——๐—ถ๐˜ƒ๐—ฒ ๐—ถ๐—ป๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—˜๐˜ƒ๐—ถ๐—ฑ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐—˜๐—ฐ๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—–๐—ฎ๐˜€๐—ฒ

Posted by Michael A. S. Guth on February 7th, 2026

๐—ก๐—œ๐—–๐—˜ ๐—ฅ๐—ฒ๐—ฐ๐—ผ๐—บ๐—บ๐—ฒ๐—ป๐—ฑ๐˜€ ๐——๐˜‚๐—ฝ๐—ถ๐—น๐˜‚๐—บ๐—ฎ๐—ฏ ๐—ณ๐—ผ๐—ฟ ๐—˜๐—ผ๐˜€๐—ถ๐—ป๐—ผ๐—ฝ๐—ต๐—ถ๐—น๐—ถ๐—ฐ ๐—–๐—ข๐—ฃ๐——: ๐—” ๐——๐—ฒ๐—ฒ๐—ฝ ๐——๐—ถ๐˜ƒ๐—ฒ ๐—ถ๐—ป๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—˜๐˜ƒ๐—ถ๐—ฑ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐—˜๐—ฐ๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—–๐—ฎ๐˜€๐—ฒ ๐—ง๐—ต๐—ฒ ๐—จ๐—ž’๐˜€ ๐—ก๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—œ๐—ป๐˜€๐˜๐—ถ๐˜๐˜‚๐˜๐—ฒ ๐—ณ๐—ผ๐—ฟ ๐—›๐—ฒ๐—ฎ๐—น๐˜๐—ต ๐—ฎ๐—ป๐—ฑ ๐—–๐—ฎ๐—ฟ๐—ฒ ๐—˜๐˜…๐—ฐ๐—ฒ๐—น๐—น๐—ฒ๐—ป๐—ฐ๐—ฒ (๐—ก๐—œ๐—–๐—˜) ๐—ต๐—ฎ๐˜€ ๐—ถ๐˜€๐˜€๐˜‚๐—ฒ๐—ฑ ๐—ณ๐—ถ๐—ป๐—ฎ๐—น ๐—ฑ๐—ฟ๐—ฎ๐—ณ๐˜ ๐—ด๐˜‚๐—ถ๐—ฑ๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—ฟ๐—ฒ๐—ฐ๐—ผ๐—บ๐—บ๐—ฒ๐—ป๐—ฑ๐—ถ๐—ป๐—ด ๐—ฑ๐˜‚๐—ฝ๐—ถ๐—น๐˜‚๐—บ๐—ฎ๐—ฏ ๐—ฎ๐˜€ ๐—ฎ๐—ป ๐—ฎ๐—ฑ๐—ฑ-๐—ผ๐—ป ๐—บ๐—ฎ๐—ถ๐—ป๐˜๐—ฒ๐—ป๐—ฎ๐—ป๐—ฐ๐—ฒ ๐˜๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐˜† ๐—ณ๐—ผ๐—ฟ ๐—ฎ ๐˜€๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ณ๐—ถ๐—ฐ, ๐—ต๐—ถ๐—ด๐—ต-๐—ป๐—ฒ๐—ฒ๐—ฑ ๐—–๐—ข๐—ฃ๐—— ๐—ฝ๐—ผ๐—ฝ๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป. ๐—ง๐—ต๐—ถ๐˜€ ๐—บ๐—ฎ๐—ฟ๐—ธ๐˜€ ๐—ฎ ๐—ฝ๐—ถ๐˜ƒ๐—ผ๐˜๐—ฎ๐—น ๐˜€๐—ต๐—ถ๐—ณ๐˜ ๐˜๐—ผ๐˜„๐—ฎ๐—ฟ๐—ฑ๐˜€ ๐—ฝ๐—ฟ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฐ๐—ถ๐—ป๐—ฒ ๐—ถ๐—ป ๐—ฐ๐—ต๐—ฟ๐—ผ๐—ป๐—ถ๐—ฐ ๐—ฟ๐—ฒ๐˜€๐—ฝ๐—ถ๐—ฟ๐—ฎ๐˜๐—ผ๐—ฟ๐˜† ๐—ฑ๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ. […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐—ก๐—œ๐—–๐—˜ ๐—ฅ๐—ฒ๐—ฐ๐—ผ๐—บ๐—บ๐—ฒ๐—ป๐—ฑ๐˜€ ๐——๐˜‚๐—ฝ๐—ถ๐—น๐˜‚๐—บ๐—ฎ๐—ฏ ๐—ณ๐—ผ๐—ฟ ๐—˜๐—ผ๐˜€๐—ถ๐—ป๐—ผ๐—ฝ๐—ต๐—ถ๐—น๐—ถ๐—ฐ ๐—–๐—ข๐—ฃ๐——: ๐—” ๐——๐—ฒ๐—ฒ๐—ฝ ๐——๐—ถ๐˜ƒ๐—ฒ ๐—ถ๐—ป๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—˜๐˜ƒ๐—ถ๐—ฑ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐—˜๐—ฐ๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—–๐—ฎ๐˜€๐—ฒ
Read More »

The 2026 Transatlantic Market Access Pivot: An Architectural Framework

Posted by Michael A. S. Guth on January 22nd, 2026

Market Access 2026: Transatlantic Pivot Toolkit A Strategic Resource for Founders & VCs Navigating the EU JSC & NHS Threshold Shifts Prepared by Michael A. S. Guth, Ph.D., J.D. | Strategic Systems Architect for High-Complexity Biologics, Drugs, and Device combinations Executive Summary The 2026 regulatory-access landscape has fundamentally shifted with two parallel developments: EU’s Joint […]

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on The 2026 Transatlantic Market Access Pivot: An Architectural Framework
Read More »

๐๐ž๐ฒ๐จ๐ง๐ ๐‚๐Ž๐•๐ˆ๐ƒ-๐Ÿ๐Ÿ—: ๐“๐ก๐ž ๐๐ž๐ฑ๐ญ ๐…๐ซ๐จ๐ง๐ญ๐ข๐ž๐ซ๐ฌ ๐Ÿ๐จ๐ซ ๐ฆ๐‘๐๐€ ๐š๐ง๐ ๐ƒ๐ž๐ฅ๐ข๐ฏ๐ž๐ซ๐ฒ ๐๐ฅ๐š๐ญ๐Ÿ๐จ๐ซ๐ฆ๐ฌ ๐ข๐ง ๐†๐ฅ๐จ๐›๐š๐ฅ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐ข๐ณ๐š๐ญ๐ข๐จ๐ง

Posted by Michael A. S. Guth on January 15th, 2026

๐“๐ก๐ž ๐ซ๐š๐ฉ๐ข๐ ๐ฆ๐š๐ญ๐ฎ๐ซ๐š๐ญ๐ข๐จ๐ง ๐จ๐Ÿ ๐ฆ๐‘๐๐€-๐‹๐๐ ๐ญ๐ž๐œ๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐ข๐ฌ ๐œ๐š๐ญ๐š๐ฅ๐ฒ๐ณ๐ข๐ง๐  ๐š ๐ง๐ž๐ฐ ๐ž๐ซ๐š ๐ข๐ง ๐ฏ๐š๐œ๐œ๐ข๐ง๐จ๐ฅ๐จ๐ ๐ฒ, ๐ฆ๐จ๐ฏ๐ข๐ง๐  ๐๐ž๐œ๐ข๐ฌ๐ข๐ฏ๐ž๐ฅ๐ฒ ๐›๐ž๐ฒ๐จ๐ง๐ ๐ฉ๐š๐ง๐๐ž๐ฆ๐ข๐œ ๐ซ๐ž๐ฌ๐ฉ๐จ๐ง๐ฌ๐ž. ๐“๐ก๐ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐จ๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐ฌ๐ž๐ฏ๐ž๐ซ๐š๐ฅ ๐œ๐จ๐ง๐ฏ๐ž๐ซ๐ ๐ž๐ง๐ญ ๐ญ๐ซ๐š๐œ๐ค๐ฌ: ๐๐ฅ๐š๐ญ๐Ÿ๐จ๐ซ๐ฆ ๐„๐ฑ๐ฉ๐š๐ง๐ฌ๐ข๐จ๐ง: ๐“๐ก๐ž ๐œ๐จ๐ซ๐ž ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐งโ€”๐ฎ๐ฌ๐ข๐ง๐  ๐‹๐๐๐ฌ ๐ญ๐จ ๐๐ž๐ฅ๐ข๐ฏ๐ž๐ซ ๐‘๐๐€ ๐ฌ๐ž๐ช๐ฎ๐ž๐ง๐œ๐ž๐ฌ ๐ž๐ง๐œ๐จ๐๐ข๐ง๐  ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐ž๐ง๐ฌโ€”๐ข๐ฌ ๐›๐ž๐ข๐ง๐  ๐๐ž๐ฉ๐ฅ๐จ๐ฒ๐ž๐ ๐š๐ ๐š๐ข๐ง๐ฌ๐ญ ๐ก๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐œ๐š๐ฅ๐ฅ๐ฒ ๐ข๐ง๐ญ๐ซ๐š๐œ๐ญ๐š๐›๐ฅ๐ž ๐ฉ๐š๐ญ๐ก๐จ๐ ๐ž๐ง๐ฌ. ๐…๐จ๐ซ ๐‡๐ˆ๐•, ๐ ๐ž๐ซ๐ฆ๐ฅ๐ข๐ง๐ž-๐ญ๐š๐ซ๐ ๐ž๐ญ๐ข๐ง๐  ๐ฌ๐ญ๐ซ๐š๐ญ๐ž๐ ๐ข๐ž๐ฌ ๐ฐ๐ข๐ญ๐ก ๐ฌ๐ž๐ช๐ฎ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐ฆ๐‘๐๐€ ๐›๐จ๐จ๐ฌ๐ญ๐ž๐ซ๐ฌ ๐š๐ข๐ฆ ๐ญ๐จ ๐ ๐ฎ๐ข๐๐ž […]

Posted in Pharma and Medical Device Comments Off on ๐๐ž๐ฒ๐จ๐ง๐ ๐‚๐Ž๐•๐ˆ๐ƒ-๐Ÿ๐Ÿ—: ๐“๐ก๐ž ๐๐ž๐ฑ๐ญ ๐…๐ซ๐จ๐ง๐ญ๐ข๐ž๐ซ๐ฌ ๐Ÿ๐จ๐ซ ๐ฆ๐‘๐๐€ ๐š๐ง๐ ๐ƒ๐ž๐ฅ๐ข๐ฏ๐ž๐ซ๐ฒ ๐๐ฅ๐š๐ญ๐Ÿ๐จ๐ซ๐ฆ๐ฌ ๐ข๐ง ๐†๐ฅ๐จ๐›๐š๐ฅ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐ข๐ณ๐š๐ญ๐ข๐จ๐ง
Read More »

๐—”๐—ฅ๐—˜ ๐—ช๐—˜ ๐—ก๐—ข๐—ช ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—•๐—จ๐—ฆ๐—œ๐—ก๐—˜๐—ฆ๐—ฆ ๐—ข๐—™ ๐—ฅ๐—˜๐—œ๐— ๐—•๐—จ๐—ฅ๐—ฆ๐—œ๐—ก๐—š “๐—ก๐—ข๐—ก-๐—œ๐—ก๐—™๐—˜๐—ฅ๐—œ๐—ข๐—ฅ?”

Posted by Michael A. S. Guth on January 8th, 2026

๐—–๐—ต๐—ฎ๐—น๐—น๐—ฒ๐—ป๐—ด๐—ฒ ๐˜๐—ต๐—ฒ ๐—ฝ๐—ฟ๐—ฒ๐—บ๐—ถ๐˜€๐—ฒ ๐—ผ๐—ณ ๐—ฐ๐—ฒ๐—น๐—ฒ๐—ฏ๐—ฟ๐—ฎ๐˜๐—ถ๐—ป๐—ด ๐—ป๐—ผ๐—ป-๐—ถ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ถ๐—ผ๐—ฟ๐—ถ๐˜๐˜† ๐—ถ๐—ป ๐—ฎ ๐—บ๐—ฎ๐˜๐˜‚๐—ฟ๐—ฒ ๐—บ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฎ๐—ป๐—ฑ ๐—พ๐˜‚๐—ฒ๐˜€๐˜๐—ถ๐—ผ๐—ป ๐˜๐—ต๐—ฒ ๐—ต๐—ฒ๐—ฎ๐—น๐˜๐—ต ๐—ฒ๐—ฐ๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น๐—ฒ. ๐—›๐—ฒ๐—ฎ๐—ฑ๐—น๐—ถ๐—ป๐—ฒ: ๐—” ๐—ก๐—ฒ๐˜„ ๐—ฃ๐—ถ๐—น๐—น ๐—ณ๐—ผ๐—ฟ ๐—›๐—œ๐—ฉ: ๐—œ๐—ป๐—ฐ๐—ฟ๐—ฒ๐—บ๐—ฒ๐—ป๐˜๐—ฎ๐—น ๐—–๐—ต๐—ฎ๐—ป๐—ด๐—ฒ ๐—ผ๐—ฟ ๐—ฃ๐—ฟ๐—ถ๐—ฐ๐—ฒ๐—ฑ ๐—ฎ๐˜€ ๐—œ๐—ป๐—ป๐—ผ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป? ๐—š๐—ถ๐—น๐—ฒ๐—ฎ๐—ฑ’๐˜€ ๐—”๐—ฅ๐—ง๐—œ๐—ฆ๐—ง๐—ฅ๐—ฌ-๐Ÿฎ ๐˜๐—ฟ๐—ถ๐—ฎ๐—น ๐˜€๐—ต๐—ผ๐˜„๐˜€ ๐—ถ๐˜๐˜€ ๐—ป๐—ฒ๐˜„ ๐—•๐—œ๐—–/๐—Ÿ๐—˜๐—ก ๐˜€๐—ถ๐—ป๐—ด๐—น๐—ฒ-๐˜๐—ฎ๐—ฏ๐—น๐—ฒ๐˜ ๐—ฟ๐—ฒ๐—ด๐—ถ๐—บ๐—ฒ๐—ป ๐—ถ๐˜€ ๐—ป๐—ผ๐—ป-๐—ถ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ถ๐—ผ๐—ฟ ๐˜๐—ผ ๐—ถ๐˜๐˜€ ๐—ผ๐˜„๐—ป ๐—ฏ๐—น๐—ผ๐—ฐ๐—ธ๐—ฏ๐˜‚๐˜€๐˜๐—ฒ๐—ฟ, ๐—•๐—œ๐—ž๐—ง๐—”๐—ฅ๐—ฉ๐—ฌ, ๐—ณ๐—ผ๐—ฟ ๐˜ƒ๐—ถ๐—ฟ๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฐ๐—ฎ๐—น๐—น๐˜† ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ฟ๐—ฒ๐˜€๐˜€๐—ฒ๐—ฑ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€. ๐—ง๐—ต๐—ฒ ๐˜€๐—ฐ๐—ถ๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ถ๐˜€ ๐˜€๐—ผ๐˜‚๐—ป๐—ฑ, ๐—ฏ๐˜‚๐˜ ๐—ถ๐˜ ๐—ฝ๐—ฟ๐—ผ๐—บ๐—ฝ๐˜๐˜€ […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐—”๐—ฅ๐—˜ ๐—ช๐—˜ ๐—ก๐—ข๐—ช ๐—œ๐—ก ๐—ง๐—›๐—˜ ๐—•๐—จ๐—ฆ๐—œ๐—ก๐—˜๐—ฆ๐—ฆ ๐—ข๐—™ ๐—ฅ๐—˜๐—œ๐— ๐—•๐—จ๐—ฅ๐—ฆ๐—œ๐—ก๐—š “๐—ก๐—ข๐—ก-๐—œ๐—ก๐—™๐—˜๐—ฅ๐—œ๐—ข๐—ฅ?”
Read More »

A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara

Posted by Michael A. S. Guth on January 8th, 2026

The MajesTEC-3 results for teclistamab + daratumumab (Tec-Dara)ย in relapsed/refractory multiple myeloma (RRMM) aren’t just an incremental gainโ€”they represent a potential paradigm shift. The FDA’s concurrent award of aย priority review voucherย underscores its transformative potential. Let’s break down the data that’s changing the standard of care: ๐Ÿ”ฌ Unprecedented Efficacy in the 1-3 Prior Lines Setting: โ€ขย PFS:ย Hazard Ratio […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara
Read More »

๐–๐ก๐ฒ “๐•๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐’๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐ ” ๐ข๐ฌ ๐๐จ ๐‹๐จ๐ง๐ ๐ž๐ซ ๐„๐ง๐จ๐ฎ๐ ๐ก ๐Ÿ๐จ๐ซ ๐Ž๐ซ๐ฉ๐ก๐š๐ง ๐†๐๐‚๐‘๐ฌ

Posted by Michael A. S. Guth on January 5th, 2026

๐…๐จ๐ซ ๐ฒ๐ž๐š๐ซ๐ฌ, ๐ญ๐ก๐ž ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐ซ๐ž๐ฅ๐ข๐ž๐ ๐จ๐ง ๐ญ๐ซ๐š๐๐ข๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ฏ๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐ฌ๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐  ๐ญ๐จ ๐Ÿ๐ข๐ง๐ ๐ง๐ž๐ž๐๐ฅ๐ž๐ฌ ๐ข๐ง ๐ญ๐ก๐ž “๐ƒ๐š๐ซ๐ค ๐†๐ž๐ง๐จ๐ฆ๐ž” ๐ก๐š๐ฒ๐ฌ๐ญ๐š๐œ๐ค. ๐๐ฎ๐ญ ๐Ÿ๐จ๐ซ ๐จ๐ซ๐ฉ๐ก๐š๐ง ๐ญ๐š๐ซ๐ ๐ž๐ญ๐ฌ ๐ฅ๐ข๐ค๐ž ๐†๐๐‘๐Ÿ๐Ÿ’๐Ÿ—, ๐ฐ๐ก๐ž๐ซ๐ž ๐ฅ๐ข๐ ๐š๐ง๐ ๐œ๐ก๐ž๐ฆ๐ข๐ฌ๐ญ๐ซ๐ฒ ๐ข๐ฌ ๐ฎ๐ง๐๐ž๐Ÿ๐ข๐ง๐ž๐, ๐ฐ๐ž ๐ง๐ž๐ž๐ ๐ฆ๐จ๐ซ๐ž ๐ญ๐ก๐š๐ง ๐š ๐›๐ž๐ญ๐ญ๐ž๐ซ ๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ž๐ง๐ ๐ข๐ง๐ž. ๐–๐ž ๐ง๐ž๐ž๐ ๐š ๐†๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐ฏ๐ž ๐„๐ง๐ ๐ข๐ง๐ž. ๐€๐ฌ ๐ฉ๐š๐ซ๐ญ ๐จ๐Ÿ ๐ฆ๐ฒ ๐ฅ๐š๐ญ๐ž๐ฌ๐ญ “๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐š๐ฅ ๐๐ฅ๐ฎ๐ž๐ฉ๐ซ๐ข๐ง๐ญ” ๐Ÿ๐จ๐ซ ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐“๐จ๐๐š๐ฒ, ๐ˆโ€™๐ฏ๐ž ๐จ๐ฎ๐ญ๐ฅ๐ข๐ง๐ž๐ ๐ฐ๐ก๐ฒ […]

Posted in AI Governance, Neuroplasticity, Pharma and Medical Device Comments Off on ๐–๐ก๐ฒ “๐•๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐’๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐ ” ๐ข๐ฌ ๐๐จ ๐‹๐จ๐ง๐ ๐ž๐ซ ๐„๐ง๐จ๐ฎ๐ ๐ก ๐Ÿ๐จ๐ซ ๐Ž๐ซ๐ฉ๐ก๐š๐ง ๐†๐๐‚๐‘๐ฌ
Read More »

๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ

Posted by Michael A. S. Guth on January 3rd, 2026

๐“๐ก๐ž “๐๐ฎ๐ซ๐ฉ๐ฅ๐ž ๐’๐ช๐ฎ๐ข๐ซ๐ซ๐ž๐ฅ” ๐“๐š๐ฅ๐ž๐ง๐ญ ๐†๐š๐ฉ Recruiters often call this the โ€œpurple squirrelโ€ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ
Read More »
« Older Entries
Newer Entries »